Health Care • Biotechnology: Pharmaceutical Preparations
$36.39 ▲ +0.00
(0.00%)
MKT CAP: $1.45B • VOL: 619.0K
52W L $19 52W H $37
PCRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $726.4M | $701.0M | $675.0M |
| YoY Revenue Growth % | +3.6% | +3.9% | — |
| Gross Profit | $576.7M | $530.5M | — |
| Gross Margin % | 79.4% | 75.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $19.2M | -$73.4M | $87.7M |
| Operating Margin % | 2.6% | -10.5% | 13.0% |
| Net Income (GAAP) | $7.0M | -$99.6M | $42.0M |
| EBITDA (Normalized) | $31.5M | -$64.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $152.0M | $189.4M | $154.6M |
| Capital Expenditures (CapEx) | $15.3M | $10.6M | — |
| Free Cash Flow (FCF) | $136.7M | $178.8M | $154.6M |
| FCF Margin % | 18.8% | 25.5% | 22.9% |
| Return on Invested Capital (ROIC %) | 1.7% | -6.5% | — |
| Cash & Short-Term Equivalents | $158.5M | $276.8M | — |
| Total Debt (Short + Long Term) | $372.2M | $383.5M | — |
| Total Stockholders' Equity | $693.1M | $778.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PCRX.